Paul Rosenberg, M.D.

Associated Investigator
E-mail: prosenb9@jhmi.edu

Publications

Clark E, Perin J, Hermann N, Brawman-Mintzer O, Lanctot K, Lerner A, Mintzer J, Padala P, Rosenberg P, Smi S, Shade D, van Dyck C, Porteinsson A. Effects of methylphenidate on neuropsychiatric symptoms of Alzheimer’s disease: Evidence from the ADMET 2 study. Alzheimers Dement, 2023; 9: e12403.
Chan C, Pettigrew C, Soldan A, Zhu Y, Wang M-C, Albert M, Rosenberg P. Association between late life neuropsychiatric symptoms and cognitive decline in relation to white matter hyperintensities and amyloid burden, Journal of Alzheimer’s Disease, 2022; 86: 1415-1426.
Nowrangi MA, Marano C, Oishi K, Mori S, Sair HI, Outen J, Leoutsakos J, Lyketsos C, Rosenberg PB. The association of neuropsychiatric symptoms with regional brain volumes from patients in a tertiary multi-disciplinary memory clinic. Int Psychogeriatr. 2021; 33:233-244.
Chan C, Soldan A, Pettigrew C, Wang M-C, Wang J, Albert M, Rosenberg P. Depressive symptoms in relation to clinical symptom onset of mild cognitive impairment. International Psychogeriatrics 2018; 31: 561-569.
Rosenberg PB, Drye LT, Porsteinsson AP, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Weintraub D, Newell J, Yesavage J, Lyketsos CG. Change in agitation in Alzheimer’s disease in the placebo arm of a nine-week controlled trial. Int Psychogeriatr 2015; 27: 2059-2067.

Primary Appointment in Psychiatry and Behavioral Science